A Landscape of Therapeutic Cooperativity in KRAS Mutant Cancers Reveals Principles for Controlling Tumor Evolution

Cell Reports - United States
doi 10.1016/j.celrep.2017.07.006
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

MTORC1/2 Inhibition as a Therapeutic Strategy for PIK3CA Mutant Cancers

Molecular Cancer Therapeutics
Cancer ResearchOncology
2018English

Mutant Kras Copy Number Defines Metabolic Reprogramming and Therapeutic Susceptibilities

Nature
Multidisciplinary
2016English

MA27.06 Therapeutic Silencing of Oncogenic KRAS With a Mutant-Specific Short Interfering RNA

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Erratum: Mechanism of MEK Inhibition Determines Efficacy in Mutant KRAS- Versus BRAF-driven Cancers

Nature
Multidisciplinary
2013English

Tissue of Origin Dictates Branched-Chain Amino Acid Metabolism in Mutant Kras-Driven Cancers

Science
MultidisciplinaryPhilosophy of ScienceHistory
2016English

Tumor Evolution as a Therapeutic Target

Cancer Discovery
Oncology
2017English

An in Vivo shRNA-Drug Screen to Identify Novel Targeted Therapy Combinations for KRAS Mutant Cancers

2014English

A Recombinant Chimeric Protein Specifically Induces Mutant KRAS Degradation and Potently Inhibits Pancreatic Tumor Growth

Oncotarget
Oncology
2016English

Allosteric Inhibitors Target KRAS in a Mutant-Specific Manner

Cancer Discovery
Oncology
2013English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy